News
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Lisata Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research reaffirms BUY rating for Lisata Therapeutics Inc with USD 15.00 target price. Encouraging results for certepetide in pancreatic cancer treatment. Analyst: Christian Orquera -
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Swissnet Group enlarges executive team with Roger Tabbal as CEO International and Swissnet MENA
Swissnet Group appoints Roger Tabbal as CEO International and Swissnet MENA, expanding into MENA region with IT solutions. Roger Tabbal brings 25 years of IT experience from roles at Accor. Swissnet Group aims for global IT leadership